

SECURITIES AND EXCHANGE COMMISSION

FORM CT ORDER

Confidential treatment order

Filing Date: **2013-01-17**
SEC Accession No. [999999997-13-000281](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

SOLIGENIX, INC.

CIK:[812796](#) | IRS No.: [411505029](#) | State of Incorp.:**DE** | Fiscal Year End: **1231**
Type: **CT ORDER** | Act: **34** | File No.: [000-16929](#) | Film No.: **13534790**
SIC: **2834** Pharmaceutical preparations

Mailing Address
29 EMMONS DRIVE
SUITE C-10
PRINCETON NJ 08540

Business Address
29 EMMONS DRIVE
SUITE C-10
PRINCETON NJ 08540
609-538-8200

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
January 17, 2013**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Soligenix, Inc.

File No. 000-16929 - CF#29183

Soligenix, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on December 27, 2012.

Based on representations by Soligenix, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 10.1 through December 20, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Jennifer Riegel
Special Counsel